Korea-U.S. vaccine partnership to help ease Korea's vaccine supply constraints

2021-05-24 04:31:51

Samsung Biologics signed a contract with Modena for the OEM production of the Covid-19 vaccine on 22nd local time.

This contributes to Korea's emergence as a global hub for Covid-19 vaccine production and helps the Korean government continue to implement its "dual vaccine strategy" of importing vaccines and developing and producing them in-house.

This will make Modena the fourth vaccine produced domestically after AstraZeneca, Novavax, and Sputnik V.

Samsung Biologics will also become the first Korean company to produce mRNA vaccines. (Yonhap News Agency)

covid vaccine Moderna Korea

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tesla's (TSLA.O) shares fell as much as 5% in pre-market trading after its fourth-quarter deliveries fell short of expectations.
                            2025-01-02

                                    Tesla (TSLA.O) produced 22,727 other models in the fourth quarter, compared with market forecasts of 22,790.
                            2025-01-02

                                    Yunding Technology: The company currently has no self-owned AI hardware products for sale
                            2025-01-02

                                    Tesla (TSLA.O) Model 3/Y production in the fourth quarter of 2024 was 436,718 units.
                            2025-01-02

                                    Tesla (TSLA.O) shares fell 2.7% in pre-market trading.
                            2025-01-02